KMT2A

KMT2A
Identifiers
AliasesKMT2A, ALL-1, CXXC7, HRX, HTRX1, MLL, MLL/GAS7, MLL1, MLL1A, TET1-MLL, TRX1, WDSTS, MLL-AF9, lysine methyltransferase 2A, Histone-lysine N-methyltransferase HRX, ALL1, HTRX
External IDsMGI: 96995; GeneCards: KMT2A
Available structures
PDBOrtholog search: PDBe RCSB
Enzyme activity
EC #BRENDAExPASyKEGGMetaCyc
2.1.1.364↗↗↗↗
Orthologs
DatabasesNCBI: entry; OMA: entry
SpeciesHumanMouse
Entrez

4297

214162

Ensembl

ENSG00000118058

ENSMUSG00000002028

UniProt

Q03164

P55200

RefSeq (mRNA)

NM_001197104
NM_005933
NM_024891

NM_001081049
NM_001357549

RefSeq (protein)

NP_001184033
NP_005924

NP_001344478

Location (UCSC)Chr 11: 118.44 – 118.53 MbChr 9: 44.71 – 44.79 Mb
PubMed search
Wikidata
View/Edit HumanView/Edit Mouse

Histone-lysine-methyltransferase 2A is an enzyme that in humans is encoded by the KMT2A gene. It is a transcriptional coactivator and histone methyltransferase whose SET domain catalyses methylation of lysine 4 on histone H3, a chromatin modification associated with transcriptional activation.

Histone-lysine-methyltransferase 2A regulates cell reproduction. It is active in generating blood cells (hematopoiesis) and during early development. KMT2A rearrangements are known genetic translocations of KMT2A and are a cause of acute leukemias and other cancers. Rearrangements of KMT2A are markers for diagnosis, prognosis, and treatment of acute leukemias. Mutations or dysregulation of the KMT2A protein product are also involved in several other types of cancers as well as developmental abnormalities such as Wiedemann-Steiner syndrome.

This protein belongs to the group of histone-modifying enzymes comprising transactivation domain 9aaTAD and is involved in the epigenetic maintenance of transcriptional memory. Its role as an epigenetic regulator of neuronal function is an ongoing area of research.